ClinicalTrials.gg
CompletedNCT03090737CheckMate 907Updated Dec 5, 2022Results posted

Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer

A Phase 2 interventional study of Nivolumab in Non-Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Completed at 17 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-05.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
129
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 43 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
34th of 120
129 · median 66
Started
2017
with 23 others
Phase 2
66 of 120
16 open now
Registered
41st of 120
by date
Lead sponsor
28 of 120
Bristol-Myers Squibb

Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 34th largest by enrollment, is one of 24 that started in 2017, is one of 66 in phase 2, and was the 41st registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

A study to evaluate the safety of Nivolumab in participants with advanced or metastatic non-small cell lung cancer

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non small cell lung cancer (Squamous or non-squamous)
  • At least one prior anti-cancer therapy that did not work
  • Performance Scale 0-1

Exclusion criteria

Exclusion Criteria:

  • Cancer that has spread to the brain or leptomeninges unless there is no evidence of progression by MRI for 8 weeks after treatment is complete and within 28 days before first dose of study drug
  • Active, known or suspected disease or infection
  • Prior immuno-oncology therapy
  • within 2 weeks of study drug administration

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    Nivolumab

    Specified Dose on Specified Days

    Biological: Nivolumab

Interventions

  • BiologicalNivolumab

    Specified Dose on Specified Days

    Also known as: BMS-936558, Opdivo

06

What researchers measure

Primary outcomes

  1. The Number of Participants Experiencing High Grade (Grades 3-4 and Grade 5) Drug-Related Select Adverse Events (AE)

    The number of participants who experienced at least 1 select AE of Grade 3-5, judged to be related to study drug per investigator with onset on or after first dose of study treatment and within 30 days of last dose of study treatment, divided by number of treated participants. AE grade is defined using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 criteria. The select AEs consist of pulmonary events, gastrointestinal events, hepatic events, renal events, skin events, endocrine events categories, thyroid disorders, diabetes, pituitary, adrenal disorder subcategories. Grade 3 is defined as severe or medically significant but not immediately life-threatening. Grade 4 is defined as life-threatening consequences and urgent intervention indicated. Grade 5 is defined as death related to AE.

    Time frame: From the first dose of study treatment to up to 30 days of the last dose of study treatment (up to 24 months)

Secondary outcomes

  1. Progression Free Survival (PFS)

    Progression free survival (PFS) is defined as the time between the date of randomization and the date of the first documented tumor progression accounting for subsequent therapy, based on BICR (blinded independent central review) assessments (per RECIST v1.1 criteria), or death due to any cause, whichever occurs first. Participants will be censored at the last evaluable tumor assessment on or prior to the date of subsequent therapy. Progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

    Time frame: From first dose to the date of the first documented tumor progression (up to approximately 5 months)

  2. Objective Response Rate (ORR)

    Objective Response Rate (ORR) defined as the percentage of participants with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as assessed by investigator per RECIST 1.1. Complete response is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm. Partial response is defined as at least a 30% decrease in the sum of diameters of target lesions. Radiographic tumor assessments will be conducted at Week 8 (+/- 7 days) and every 8 weeks (+/- 7 days) until up to 2 years or until disease progression (or until discontinuation of study therapy in patients receiving nivolumab beyond progression), lost to follow-up, or withdrawal of study consent.

    Time frame: From the date of first dose to the date of the initial objectively documented tumor progression or the date of subsequent therapy, whichever occurs first (up to approximately 25 months).

  3. Overall Survival (OS)

    Overall Survival (OS) is defined as the time between the first dosing date and the date of death due to any cause. For participants without documentation of death, OS will be censored on the last date the participant was known to be alive.

    Time frame: From first dosing date and the date of death due to any cause (up to approximately 4 years and 9 months)

  4. Duration of Response (DOR)

    Duration of Response (DOR) is defined as the time between the date of first confirmed response up to the date of the first documented tumor progression (per RECIST 1.1) as determined by complete response (CR) or partial response (PR), or death due to any cause, whichever occurs first. Participants who neither progress nor die will be censored on the date of their last evaluable tumor assessment. Participants who started any subsequent anti-cancer therapy (including palliative local therapy) without a prior reported progression will be censored at the last evaluable tumor assessment prior to or on the date of initiation of the subsequent anti-cancer therapy (including palliative local therapy). Complete response is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm. Partial response is defined as at least a 30% decrease in the sum of diameters of target lesions.

    Time frame: From the date of first confirmed response up to the date of the first documented tumor progression (per RECIST 1.1), or death due to any cause, whichever occurs first (up to approximately 48 months).

07

Results

Posted Mar 14, 2022

Participant flow

Participant flow — Overall Study
MilestoneNivolumab 480mg Q4W
Started129
Completed0
Not completed129
Withdrew: Other reasons1
Withdrew: Completed treatment as per protocol17
Withdrew: Maximum clinical benefit2
Withdrew: Adverse event unrelated to study drug7
Withdrew: Study drug toxicity4
Withdrew: Disease progression98

Outcome measures

PrimaryThe Number of Participants Experiencing High Grade (Grades 3-4 and Grade 5) Drug-Related Select Adverse Events (AE)

The number of participants who experienced at least 1 select AE of Grade 3-5, judged to be related to study drug per investigator with onset on or after first dose of study treatment and within 30 days of last dose of study treatment, divided by number of treated participants. AE grade is defined using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 criteria. The select AEs consist of pulmonary events, gastrointestinal events, hepatic events, renal events, skin events, endocrine events categories, thyroid disorders, diabetes, pituitary, adrenal disorder subcategories. Grade 3 is defined as severe or medically significant but not immediately life-threatening. Grade 4 is defined as life-threatening consequences and urgent intervention indicated. Grade 5 is defined as death related to AE.

Time frame:
From the first dose of study treatment to up to 30 days of the last dose of study treatment (up to 24 months)
Reported as:
Count of participants · Participants
The Number of Participants Experiencing High Grade (Grades 3-4 and Grade 5) Drug-Related Select Adverse Events (AE)
ParticipantsNivolumab 480mg Q4W
Total Participants with Grade 3-4 AE3
Total Participants with Grade 5 AE0
SecondaryProgression Free Survival (PFS)

Progression free survival (PFS) is defined as the time between the date of randomization and the date of the first documented tumor progression accounting for subsequent therapy, based on BICR (blinded independent central review) assessments (per RECIST v1.1 criteria), or death due to any cause, whichever occurs first. Participants will be censored at the last evaluable tumor assessment on or prior to the date of subsequent therapy. Progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

Time frame:
From first dose to the date of the first documented tumor progression (up to approximately 5 months)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsNivolumab 480mg Q4W
Progression Free Survival (PFS)3.68 (3.06 to 4.50)
SecondaryObjective Response Rate (ORR)

Objective Response Rate (ORR) defined as the percentage of participants with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as assessed by investigator per RECIST 1.1. Complete response is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm. Partial response is defined as at least a 30% decrease in the sum of diameters of target lesions. Radiographic tumor assessments will be conducted at Week 8 (+/- 7 days) and every 8 weeks (+/- 7 days) until up to 2 years or until disease progression (or until discontinuation of study therapy in patients receiving nivolumab beyond progression), lost to follow-up, or withdrawal of study consent.

Time frame:
From the date of first dose to the date of the initial objectively documented tumor progression or the date of subsequent therapy, whichever occurs first (up to approximately 25 months).
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsNivolumab 480mg Q4W
Objective Response Rate (ORR)17.1 (11.0 to 24.7)
SecondaryOverall Survival (OS)

Overall Survival (OS) is defined as the time between the first dosing date and the date of death due to any cause. For participants without documentation of death, OS will be censored on the last date the participant was known to be alive.

Time frame:
From first dosing date and the date of death due to any cause (up to approximately 4 years and 9 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsNivolumab 480mg Q4W
Overall Survival (OS)10.58 (8.34 to 14.69)
SecondaryDuration of Response (DOR)

Duration of Response (DOR) is defined as the time between the date of first confirmed response up to the date of the first documented tumor progression (per RECIST 1.1) as determined by complete response (CR) or partial response (PR), or death due to any cause, whichever occurs first. Participants who neither progress nor die will be censored on the date of their last evaluable tumor assessment. Participants who started any subsequent anti-cancer therapy (including palliative local therapy) without a prior reported progression will be censored at the last evaluable tumor assessment prior to or on the date of initiation of the subsequent anti-cancer therapy (including palliative local therapy). Complete response is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm. Partial response is defined as at least a 30% decrease in the sum of diameters of target lesions.

Time frame:
From the date of first confirmed response up to the date of the first documented tumor progression (per RECIST 1.1), or death due to any cause, whichever occurs first (up to approximately 48 months).
Reported as:
Median · Months
Duration of Response (DOR)
MonthsNivolumab 480mg Q4W
Duration of Response (DOR)35.45 (10.87 to 47.31)
Post-hocThe Number of Participants Experiencing High Grade (Grades 3-4 and Grade 5) Drug-Related Select Adverse Events (AE) - Extended Collection

The number of participants who experienced at least 1 select AE of Grade 3-5, judged to be related to study drug per investigator with onset on or after first dose of study treatment and within 30 days of last dose of study treatment, divided by number of treated participants. AE grade is defined using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 criteria. The select AEs consist of pulmonary events, gastrointestinal events, hepatic events, renal events, skin events, endocrine events categories, thyroid disorders, diabetes, pituitary, adrenal disorder subcategories. Grade 3 is defined as severe or medically significant but not immediately life-threatening. Grade 4 is defined as life-threatening consequences and urgent intervention indicated. Grade 5 is defined as death related to AE. Note: This outcome measure represents an update to the primary endpoint to include additional data collection that occurred after the primary completion date.

Time frame:
From the first dose of study treatment to up to 30 days of the last dose of study treatment (up to 25 months)
Reported as:
Count of participants · Participants
The Number of Participants Experiencing High Grade (Grades 3-4 and Grade 5) Drug-Related Select Adverse Events (AE) - Extended Collection
ParticipantsNivolumab 480mg Q4W
Total Participants with Grade 3-4 AE6
Total Participants with Grade 5 AE0

Adverse events

Collected over Participants were assessed for all-cause mortality from their enrollment to study completion, (up to approximately 4 years and 9 months). SAEs and Other AEs were assessed from first dose to 100 days following last dose (up to approximately 27 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nivolumab 480mg Q4W105/129 (81.4%)56/129 (43.4%)111/129 (86%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventNivolumab 480mg Q4W
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)37/129
PneumoniaInfections and infestations6/129
PneumothoraxRespiratory, thoracic and mediastinal disorders2/129
AnaemiaBlood and lymphatic system disorders1/129
PancytopeniaBlood and lymphatic system disorders1/129
Cardiac tamponadeCardiac disorders1/129
ColitisGastrointestinal disorders1/129
NauseaGastrointestinal disorders1/129
Oesophageal ulcerGastrointestinal disorders1/129
VomitingGastrointestinal disorders1/129
Most frequent other events
Showing 10 of 33
Most frequent other events
EventNivolumab 480mg Q4W
AnaemiaBlood and lymphatic system disorders37/129
Blood alkaline phosphatase increasedInvestigations32/129
RashSkin and subcutaneous tissue disorders26/129
DiarrhoeaGastrointestinal disorders24/129
PruritusSkin and subcutaneous tissue disorders24/129
DyspnoeaRespiratory, thoracic and mediastinal disorders23/129
NauseaGastrointestinal disorders22/129
Decreased appetiteMetabolism and nutrition disorders21/129
FatigueGeneral disorders19/129
HeadacheNervous system disorders17/129

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Nivolumab 480mg Q4W
Mean61.8 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)Nivolumab 480mg Q4W
Female34
Male95
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nivolumab 480mg Q4W
Hispanic or Latino1
Not Hispanic or Latino41
Unknown or Not Reported87
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nivolumab 480mg Q4W
American Indian or Alaska Native0
Asian26
Native Hawaiian or Other Pacific Islander0
Black or African American3
White95
More than one race0
Unknown or Not Reported5
08

Study locations

17 sites
  • Alabama Oncology
    Birmingham, Alabama 35205, United States
  • Los Angeles Hematology Oncology Medical Group
    Los Angeles, California 90017, United States
  • St Vincent Frontier Cancer Center
    Billings, Montana 59102, United States
  • Broome Oncology
    Johnson City, New York 13790, United States
  • Guthrie Medical Group Sayre
    Sayre, Pennsylvania 18840, United States
  • Local Institution - 0015
    Kingston, Ontario K7L 2V7, Canada
  • Local Institution - 0014
    Oshawa, Ontario L1G 2B9, Canada
  • Local Institution - 0001
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution - 0017
    Nagoya, Aichi 4648681, Japan
  • Local Institution - 0023
    Osaka-shi, Osaka 5418567, Japan
  • Local Institution - 0018
    Koto-ku, Tokyo 1358550, Japan
  • Local Institution - 0016
    Tokyo, 1040045, Japan
  • Local Institution - 0003
    Craiova, 200347, Romania
  • Local Institution - 0006
    Sector 2, 022328, Romania
  • Local Institution - 0011
    Port Elizabeth, Eastern Cape 6045, South Africa
  • Local Institution - 0013
    Parktown, Johannesburg, Gauteng 2193, South Africa
  • Local Institution - 0012
    George, Western CAPE 6530, South Africa
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Feb 2021, 44 months.

Results were first posted in Mar 2022, 1 year after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 44 months is above that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2017
First posted
Mar 27, 2017
StartActual
Jun 2, 2017
Primary completionActual
Feb 16, 2021
CompletionActual
Mar 14, 2022
Results first posted
Mar 14, 2022
Last update
Dec 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03090737
Responsible party
Sponsor
First posted
Mar 27, 2017
Start date
Jun 2, 2017
Primary completion
Feb 16, 2021
Completion
Mar 14, 2022
Results posted
Mar 14, 2022
Last update
Dec 5, 2022

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion